1. Home
  2. FGEN vs NTIP Comparison

FGEN vs NTIP Comparison

Compare FGEN & NTIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FGEN
  • NTIP
  • Stock Information
  • Founded
  • FGEN 1993
  • NTIP 1990
  • Country
  • FGEN United States
  • NTIP United States
  • Employees
  • FGEN N/A
  • NTIP N/A
  • Industry
  • FGEN Biotechnology: Pharmaceutical Preparations
  • NTIP Multi-Sector Companies
  • Sector
  • FGEN Health Care
  • NTIP Miscellaneous
  • Exchange
  • FGEN Nasdaq
  • NTIP Nasdaq
  • Market Cap
  • FGEN 34.5M
  • NTIP 32.9M
  • IPO Year
  • FGEN 2014
  • NTIP 1998
  • Fundamental
  • Price
  • FGEN $0.55
  • NTIP $1.39
  • Analyst Decision
  • FGEN
  • NTIP
  • Analyst Count
  • FGEN 0
  • NTIP 0
  • Target Price
  • FGEN N/A
  • NTIP N/A
  • AVG Volume (30 Days)
  • FGEN 705.5K
  • NTIP 11.7K
  • Earning Date
  • FGEN 02-24-2025
  • NTIP 03-07-2025
  • Dividend Yield
  • FGEN N/A
  • NTIP 7.19%
  • EPS Growth
  • FGEN N/A
  • NTIP N/A
  • EPS
  • FGEN N/A
  • NTIP N/A
  • Revenue
  • FGEN $180,015,000.00
  • NTIP $1,881,000.00
  • Revenue This Year
  • FGEN $21.91
  • NTIP N/A
  • Revenue Next Year
  • FGEN N/A
  • NTIP N/A
  • P/E Ratio
  • FGEN N/A
  • NTIP N/A
  • Revenue Growth
  • FGEN 16.15
  • NTIP 129.39
  • 52 Week Low
  • FGEN $0.18
  • NTIP $1.22
  • 52 Week High
  • FGEN $2.80
  • NTIP $2.25
  • Technical
  • Relative Strength Index (RSI)
  • FGEN 58.51
  • NTIP 53.56
  • Support Level
  • FGEN $0.46
  • NTIP $1.36
  • Resistance Level
  • FGEN $0.51
  • NTIP $1.41
  • Average True Range (ATR)
  • FGEN 0.04
  • NTIP 0.02
  • MACD
  • FGEN 0.00
  • NTIP 0.00
  • Stochastic Oscillator
  • FGEN 72.57
  • NTIP 70.00

About FGEN FibroGen Inc

FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The Company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.

About NTIP Network-1 Technologies Inc.

Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property rights. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.

Share on Social Networks: